Radiprodil

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Radiprodil ( ; developmental code name RGH-896) is an NR2B (GluN2B; GRIN2B) subunit-selective NMDA receptor negative allosteric modulator which is under development for the treatment of neurodevelopmental disorders, focal cortical dysplasia, tuberous sclerosis, behavioral disorders, and seizures. It is taken orally. The drug is being developed by GRIN Therapeutics. As of December 2025, it is in phase 3 clinical trials for neurodevelopmental disorders, phase 1/2 trials for focal cortical dysplasia and tuberous sclerosis, and phase 1 trials for behavioral disorders and seizures. The drug was first described in the scientific literature by 2003.

Radiprodil ( ; developmental code name RGH-896) is an NR2B (GluN2B; GRIN2B) subunit-selective NMDA receptor negative allosteric modulator which is under development for the treatment of neurodevelopmental disorders, focal cortical dysplasia, tuberous sclerosis, behavioral disorders, and seizures. It is taken orally. The drug is being developed by GRIN Therapeutics. As of December 2025, it is in phase 3 clinical trials for neurodevelopmental disorders, phase 1/2 trials for focal cortical dysplasia and tuberous sclerosis, and phase 1 trials for behavioral disorders and seizures. The drug was first described in the scientific literature by 2003.

See also

NMDA receptor antagonist

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370310198 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.